Figure 1. Progression-free survival in patients with agreement and discordance between scales of Memorial Sloan-Kettering Cancer Center and International Metastatic Renal Cell Carcinoma Database Consortium.
| World Journal of Oncology, ISSN 1920-4531 print, 1920-454X online, Open Access |
| Article copyright, the authors; Journal compilation copyright, World J Oncol and Elmer Press Inc |
| Journal website https://www.wjon.org |
Original Article
Volume 13, Number 2, April 2022, pages 53-58
Impact of the Discordance Between Scales of Memorial Sloan-Kettering Cancer Center and International Metastatic Renal Cell Carcinoma Database Consortium in Patients’ Prognosis With Metastatic Renal Cancer
Figures
Tables
| Characteristic | Number of patients | Percentage |
|---|---|---|
| SD: standard deviation. | ||
| Sex | 26 | 100 |
| Women | 8 | 30.8 |
| Man | 18 | 69.2 |
| Age | 26 | Median ± SD: 65 ± 10 years |
| Nephrectomy | 24/26 | 92 |
| Histology | 26 | 100 |
| Clear cells | 23 | 88 |
| Chromophobe | 1 | 6 |
| Papillary | 1 | 6 |
| Sarcomatoid pattern | 5/26 | 20 |
| State IV at diagnosis | 14/26 | 53 |
| Pulmonary metastases | 21/26 | 80 |
| Liver metastases | 6/26 | 23 |
| Brain metastases | 9/26 | 34 |
| Bone metastases | 10/26 | 38 |
| Treatment | ||
| First-line | 26 | 100 |
| Targeted therapy | 24 | 92 |
| Immunotherapy | 2 | 8 |
| Second-line | 14 | 53 |
| Targeted therapy | 11 | 42 |
| Immunotherapy | 3 | 11 |
| Third-line | 8 | 30 |
| Targeted therapy | 6 | 23 |
| Immunotherapy | 2 | 7 |
| Metastasectomy | 9 | 34 |
| Palliative radiotherapy | 6 | 23 |
| Use of bisphosphonates | 4 | 15 |
| Population | Number of patients (%) | Median survival (months) |
|---|---|---|
| MSKCC: Memorial Sloan-Kettering Cancer Center; IMDC: Metastatic Renal Cell Carcinoma Database Consortium. | ||
| Global | 26 (100%) | 91.1 |
| Risk per MSKCC | ||
| Favorable | 5 (19.2%) | 158.8 |
| Intermediate | 16 (61.6%) | 45.1 |
| Poor | 5 (19.2%) | 5 |
| Risk per IMDC | ||
| Favorable | 4 (15.38%) | 91.1 |
| Intermediate | 14 (53.84%) | 120.2 |
| Poor | 8 (30.76%) | 6.8 |
| Category | Frequency | Overall survival | Progression-free survival |
|---|---|---|---|
| MSKCC: Memorial Sloan-Kettering Cancer Center; IMDC: Metastatic Renal Cell Carcinoma Database Consortium. | |||
| Agreement between scales | 16 (61%) | 112 months | 18.9 months |
| Discordance (MSKCC vs. IMDC) | 10 (38%) | 32.8 months | 3.1 months |
| Favorable to intermediate | 2 | ||
| Intermediate to poor | 5 | ||
| Intermediate to Favorable | 1 | ||
| Poor to intermediate | 2 | ||
| Log rank | |||
| Xi2 | 0.000 | 3.902 | |
| Significance | 0.990 | 0.048 | |